Abstract
In the treatment of chronic hepatitis B (CHB) patients with drug resistance, rescue combination therapy leads to viral suppression in almost all patients. However, once it is achieved, lifelong maintenance especially, by using combination therapy is not always possible in a significant proportion of patients. At present, there is no consensus on whether it is possible to switch to monotherapy from combination therapy. However, there is robust evidence to support step-down therapy, which involves switching from combination therapy to monotherapy in antiviral resistant CHB patients who achieve complete viral response from combination therapy. We review the evidence in favor of switching to monotherapy in antiviral resistant CHB patients who achieve complete viral response by combination therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 711-717 |
| Number of pages | 7 |
| Journal | Future Virology |
| Volume | 13 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 2018 |
Bibliographical note
Publisher Copyright:© 2018 2018 Future Medicine Ltd.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Virology
Fingerprint
Dive into the research topics of 'Step-down strategy in antiviral resistant chronic hepatitis B patients who achieved viral suppression with rescue combination therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver